Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of PepGen Inc. regarding a class action lawsuit due to allegations of misleading statements related to the company's lead product candidate, PGN-EDO51, and its clinical study [1][2]. Group 1: Allegations and Class Action Details - The class period for the allegations is from March 7, 2024, to March 3, 2025 [1]. - Allegations include that PGN-EDO51 was less effective and safe than claimed, and that the CONNECT2 study was dangerous or deficient for FDA approval [1]. - The lawsuit suggests that PepGen may halt the CONNECT2 study, and that the prospects for PGN-EDO51 were overstated [1]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by August 8, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case [2]. Group 3: About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

PGN-EDODM1 for DM1 - PGN-EDODM1 targets the pathogenic CUGexp repeats in DM1, aiming to restore correct splicing by liberating MBNL1[29, 30, 31, 32, 33] - In DM1 patient cells, PGN-EDODM1 treatment resulted in a 54% reduction in toxic foci and a 69% correction of mis-splicing[36] - Preclinical studies showed that multiple doses of PGN-EDODM1 led to a 99% correction of myotonia, compared to a single dose[41] - In the FREEDOM Phase 1 trial, a single 10 mg/kg dose of PGN-EDODM1 produced a mean 29% splicing correction[57] PGN-EDO51 for DMD - In a healthy volunteer study, PGN-EDO51 demonstrated exon skipping, with levels reaching 1.4% at Day 10 and 2% at Day 28 in the 15 mg/kg cohort[76] - CONNECT1 study showed that PGN-EDO51 generated encouraging levels of muscle adjusted dystrophin production of 0.70% and total dystrophin production of 0.26% after just 3 months and 4 doses at 5 mg/kg[95] - CONNECT1 study also showed high levels of mean exon 51 skipping of 2.15% after just 3 months and 4 doses at 5 mg/kg[95] EDO Platform - PepGen's EDO platform is designed for nuclear delivery of oligonucleotide therapeutics, showing up to 25X higher nuclear uptake[7, 17, 19] - EDO technology has been shown to increase cellular uptake and endosomal escape up to 24-fold[21]

PGN-EDODM1 for DM1 - PepGen's EDO platform aims to deliver higher levels of oligonucleotide to the nuclei, potentially improving the lives of people with severe neuromuscular and neurological diseases[3] - The FREEDOM-DM1 (Phase 1) trial observed a favorable emerging safety profile and a mean splicing correction of 29% after a single dose of 10 mg/kg at 28 days post-dosing[22] - Preclinical studies showed that multiple doses of PGN-EDODM1 led to greater improvement in splicing correction and myotonia compared to a single dose[35] - In DM1 patient cells, PGN-EDODM1 treatment resulted in a 54% reduction in toxic foci and a 69% correction of mis-splicing[33] - The FREEDOM trial showed a dose-dependent increase in drug tissue concentration, with approximately 12% splicing correction at 5 mg/kg and approximately 29% splicing correction at 10 mg/kg[56] PGN-EDO51 for DMD - The company is voluntarily discontinuing development of PGN-EDO51 for DMD due to the CONNECT1-EDO51 Phase 2 study results not achieving target dystrophin levels[63] - In the CONNECT1-EDO51 trial, a mean maximal exon skipping of 426% (mean increase of 35%) and a mean maximal dystrophin of 059% (mean increase of 036%) were observed after four doses of 10 mg/kg[63] EDO Platform Technology - PepGen's EDO platform is designed to solve the problem of inefficient penetration of muscle cells and the nucleus by naked oligonucleotides[13] - PepGen's EDO platform can result in up to 25X higher nuclear uptake of oligonucleotide[16] - EDO technology has been shown to increase cellular uptake and endosomal escape up to 24-fold[18]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PepGen Inc. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from March 7, 2024, to March 3, 2025, and the lead plaintiff deadline is August 8, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm [2][5]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3]. Group 3: Case Allegations - The lawsuit alleges that PepGen made false and misleading statements regarding the effectiveness and safety of PGN-EDO51, as well as the CONNECT2 study's suitability for FDA approval [4]. - It is claimed that these misrepresentations led to an overstatement of the clinical, regulatory, and commercial prospects of PGN-ED051, ultimately resulting in investor damages when the truth was revealed [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against PepGen Inc. due to alleged violations of federal securities laws, encouraging affected investors to seek legal counsel before the August 11, 2025 deadline for lead plaintiff applications in a federal class action lawsuit [3][5]. Group 1: Allegations Against PepGen - The complaint alleges that PepGen and its executives made false or misleading statements regarding the effectiveness and safety of PGN-EDO51, and failed to disclose deficiencies in the CONNECT2 study, leading to overstated clinical and commercial prospects [5]. - The FDA issued a clinical hold notice for the CONNECT2 study, indicating concerns about patient risks and deficiencies in the study [8]. Group 2: Stock Price Reactions - Following the announcement of disappointing clinical data from the CONNECT1 study, PepGen's stock price fell by $5.55, or 32.69%, closing at $11.43 on July 31, 2024 [7]. - After the FDA's clinical hold notice on December 16, 2024, PepGen's stock dropped by $0.17, or 3.63%, to close at $4.51 [9]. - On January 30, 2025, PepGen's stock fell by $0.40, or 21.74%, to close at $1.44 after updates on safety concerns in the CONNECT1 study [10]. - The stock price further declined by $0.53, or 18.86%, to close at $2.28 on March 4, 2025, following the announcement to pause the CONNECT2 study [11]. - On May 28, 2025, PepGen announced the discontinuation of its DMD programs after PGN-EDO51 failed to achieve target dystrophin levels [12]. Group 3: Legal and Investor Actions - Investors who suffered losses exceeding $50,000 in PepGen between March 7, 2024, and March 3, 2025, are encouraged to contact Faruqi & Faruqi for legal options [1]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding PepGen's conduct [14].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PepGen Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on August 8, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought PepGen securities between March 7, 2024, and March 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3]. Group 2: Case Allegations - The lawsuit alleges that PepGen made false and misleading statements regarding the effectiveness and safety of PGN-EDO51, as well as the CONNECT2 study's suitability for FDA approval [4]. - It is claimed that due to these misrepresentations, PepGen was likely to halt the CONNECT2 study, leading to overstated clinical, regulatory, and commercial prospects for PGN-ED051 [4]. - The lawsuit asserts that when the true information became public, investors suffered damages as a result of the misleading statements [4]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong reputation in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of PepGen Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its lead product candidate, PGN-EDO51, and the CONNECT2 study [1][2]. Allegations - The lawsuit claims that during the class period from March 7, 2024, to March 3, 2025, PepGen's statements regarding PGN-EDO51's effectiveness and safety were misleading [1]. - It is alleged that the phase two CONNECT2 study was dangerous or deficient for FDA approval, leading to the likelihood of halting the study [1]. - The complaint suggests that the clinical, regulatory, and commercial prospects of PGN-EDO51 were overstated, resulting in materially false public statements by the defendants [1]. Next Steps for Shareholders - Shareholders who purchased shares of PEPG during the specified timeframe are encouraged to register for the class action by August 8, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through portfolio monitoring software throughout the case lifecycle [2]. About the Law Firm - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against PepGen Inc. due to allegations of misleading statements regarding the effectiveness and safety of its drug PGN-EDO51, which has led to significant stock price declines and a federal securities class action [2][4]. Group 1: Allegations and Legal Actions - The complaint against PepGen alleges violations of federal securities laws, including false statements about the effectiveness and safety of PGN-EDO51 and deficiencies in the CONNECT2 study [4]. - Investors who purchased PepGen securities between March 7, 2024, and March 3, 2025, are encouraged to discuss their legal rights and options with Faruqi & Faruqi [1][2]. - The deadline to seek the role of lead plaintiff in the federal securities class action against PepGen is August 11, 2025 [2]. Group 2: Clinical Study Results and Stock Performance - On July 30, 2024, PepGen reported "positive clinical data" from the CONNECT1 study, but analysts noted that the results were below expectations, leading to a 32.69% drop in stock price [5][6]. - Following a clinical hold notice from the FDA on December 16, 2024, due to safety concerns, PepGen's stock fell by 3.63% [7][8]. - A subsequent update on January 29, 2025, regarding safety concerns in the CONNECT1 study led to a further 21.74% decline in stock price [9][10]. - On March 4, 2025, PepGen announced a voluntary pause of the CONNECT2 study, resulting in an 18.86% drop in stock price [10]. - On May 28, 2025, PepGen disclosed that PGN-EDO51 did not achieve target dystrophin levels and decided to discontinue its DMD programs [11].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PepGen Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on August 8, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought PepGen securities between March 7, 2024, and March 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by August 8, 2025 [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that PepGen made false and misleading statements regarding the effectiveness and safety of PGN-EDO51, the CONNECT2 study's safety for FDA approval, and the overstated clinical and commercial prospects of PGN-ED051 [4]. - It is claimed that when the true details became known, investors suffered damages due to these misleading statements [4].

Core Viewpoint - PepGen Inc. is facing a securities fraud class action lawsuit alleging misrepresentations regarding the effectiveness and safety of its lead product candidate, PGN-EDO51, during a specified period [2][3]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Eastern District of New York on behalf of investors who purchased or acquired PepGen securities between March 7, 2024, and March 3, 2025 [2][3]. - Investors are reminded of an upcoming deadline to file as lead plaintiff by August 8, 2025, which allows them to represent other class members in the litigation [3]. Group 2: Legal Representation - Bernstein Liebhard LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless there is a recovery [4]. - The firm has a strong track record, having recovered over $3.5 billion for clients since 1993 and has been recognized multiple times for its litigation success [5].